About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Senate "Patent Reform" Bill (S. 515) Voted out of Judiciary Committee | Main | EFS & PAIR News »

April 03, 2009

Comments

Don,

In the Kubin case, even Judge Rader is now running scared from SCOTUS. His treatment of the continuing validity of Deuel is puzzling as SCOTUS said in KSR (as was quoted in the opinion) that "the fact a combination was obvious to try might show that it was obvious under [section] 103." SCOTUS didn't say "would show it was obvious" but you would never believe that after this Kubin decision. If ever there was a case for an en banc hearing, this is one as this panel has, in essence, negated the previously Deuel precedent. I can just see Judge Newman going ballistic over this one (she's the only judge on the Federal Circuit not running scared from SCOTUS).

Biotech patents, R.I.P. If not overturned en banc or by the SCOTUS, this decision just killed, or at the very least cast a dark shadow on, virtually every single genetic material-based patent granted post-Deuel. Even if some patents survive based on some theory of unpredictability in cloning etc., have fun spending $$$s on expert witness/litigation/etc. to get to that point. Given the current state of the biotechnological arts, it's hard to imagine any isolated genetic material being patentable now. I'm taking my ball and going home ....

I propose that David Baltimore go ahead and mail his Nobel Prize to Judge Moore, given her clearly superior knowledge and understanding of NF-kB regulation.

The comments to this entry are closed.

June 2019

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30